Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genzyme’s Synvisc-One approved

This article was originally published in The Gray Sheet

Executive Summary

Single-injection viscosupplement is approved to treat osteoarthritis of the knee in patients who have failed to respond to more conservative therapy, the firm announces Feb. 26. On Dec. 9, FDA's Orthopedic and Rehabilitation Devices advisory panel recommended approval of Genzyme's PMA supplement for the single-dose version of Synvisc (approved in 1997). Unlike Synvisc-One, Synvisc requires three intra-articular injections at one-week intervals (1"The Gray Sheet" Dec. 15, 2008, p. 13). Genzyme says it will launch Synvisc-One "immediately.

You may also be interested in...



Anika Starts New Year With Fidia Acquisition, Direct Sales Plan

Anika Therapeutics' acquisition of Fidia Advanced Biopolymers provides a "critical mass" of hyaluronic acid-based products to market in the U.S. alongside its PMA-pending Monovisc single-injection knee osteoarthritis therapy, the firm said

FDA Panel Endorses Genzyme’s Synvisc-One Knee Therapy

FDA's Orthopedic and Rehabilitation Devices advisory panel voted unanimously last week to recommend approval of Genzyme's PMA supplement for a single-dose version of its hyaluronic acid-based osteoarthritis knee therapy

Long Hot Summer For Novel Drug Reviews Forecast At US FDA

Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.

Topics

UsernamePublicRestriction

Register

MT027159

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel